• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 18, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Nov. 18, 2024 -- For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study published online Nov. 13 in the New England Journal of Medicine.

Ania M. Jastreboff, M.D., Ph.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues performed a phase 3, double-blind trial involving 2,539 participants with obesity (1,032 of whom also had prediabetes), who were randomly assigned to receive tirzepatide at a once-weekly dose of 5, 10, or 15 mg or placebo in a 1:1:1:1 ratio. The current analysis included the participants with obesity and prediabetes who received tirzepatide or placebo for 176 weeks followed by an off-treatment period of 17 weeks.

The researchers found that the mean percentage change in body weight at 176 weeks was −12.3, −18.7, and −19.7 percent for those receiving 5-, 10-, and 15-mg tirzepatide doses, respectively, compared with −1.3 percent for those receiving placebo. Receipt of a diagnosis of type 2 diabetes occurred in fewer participants in the tirzepatide groups versus the placebo group (1.3 versus 13.3 percent; hazard ratio, 0.07). After 17 weeks off treatment, 2.4 and 13.7 percent of those who received tirzepatide and placebo, respectively, had type 2 diabetes (hazard ratio, 0.12). Apart from COVID-19, the most common adverse events were gastrointestinal, most of which were mild-to-moderate in severity.

"Tirzepatide therapy resulted in sustained weight reduction that was accompanied by a markedly lower risk of progression to type 2 diabetes than that with placebo," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted November 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.